Characterization of human immunodeficiency virus type 1 resistant to modified cyclodextrin sulphate (mCDS71) in vitro

Antiviral Chemistry and Chemotherapy

Volumn 10, Issue 1, 1999, Pages 15-21

  Mori, H ^a   Otake, T ^a   Oishi, I ^a   Kurimura, T ^b  

^a OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Amino acid sequence; Drug resistance; env region; HIV 1; mCDS71; Modified cyclodextrin sulphate

Indexed keywords

AMINO ACID; CYCLODEXTRIN DERIVATIVE; GLYCOPROTEIN GP 120; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; VIRUS CULTURE; VIRUS MUTATION;

EID: 0033028773     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029901000102     Document Type: Article

References (36)

1. Abrams DI, Kuno S, Wong R, Jeffords K, Nash M, Molaghan JB, Gorter R & Ueno R (1989) Oral dextran sulfate (UA001) in the treatment of the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. Annals of Internal Medicine 110:183-188.
2. Adachi A, Gendelman HE, Koenig S, Forks T, Willey R, Rabson A & Martin MA (1986) Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. Journal of Virology 59:284-291.
3. Baba M, Pauwels R, Balzarini J, Arnout J, Desmyter J & De Clercq E (1988) Mechanism of inhibitory effect of dextran sulfate and heparin on replication of human immunodeficiency virus in vitro. Proceedings of the National Academy of Science, USA 85:6132-6136.
4. Chen Z, Li Y, Schock HB, Hall D, Chen E & Kuo LC (1995) Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials. Journal of Biological Chemistry 270:21433-21436.
5. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Teppler H, Squires KE, Deutsch PJ & Emini EA (1995) In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
6. Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Yang T, Chodakewitz JA, Deutsch PJ, Leavitt RY, Massari FE, Mellors JW, Squires KE, Steigbigel RY, Teppler H & Emini EA (1996) Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. Journal of Virology 70:8270-8276.
7. De Clercq E, Yamamoto N, Pauwels R, Baba M, Schols D, Nakashima H, Balzarini J, Debyser Z, Murrer BA, Schwartz D, Thornton D, Bridger G, Fricker S, Henson G, Abrams M and Picker D (1992) Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proceedings of the National Academy of Sciences, USA 89:5286-5290
8. De Vreese K, Reymem D, Griffin P, Steinkasserer A, Werner G, Bridger GJ, Esté JA, James W, Henson GW, Desmyter J, Anné J & De Clercq E (1996a) The bicyclams, a new class of potent human immunodeficiency virus inhibitors, block viral entry after binding. Antiviral Research 29:209-219
9. De Vreese K, Kofler-Mongold V, Leutgeb C, Weber V, Vermeire K, Schacht S, Anné J, De Clercq E, Datema R & Werner G (1996b) The molecular target of bicyclams, potent inhibitors of human immunodeficiency virus replication. Journal of Virology 70:689-696.
10. Esté JA, Schols D, De Vreese K, Laethem KV, Vandamme A-M, Desmyter J & De Clercq E (1997) Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein. Molecular Pharmacology 52:98-104
11. Gao Q, Gu Z, Parniak MA, Cameron J, Cammack N, Boucher C & Wainberg MA (1993) The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrobial Agents and Chemotherapy 37:1390-1392.
12. Genesca J, Wang RY, Alter HJ & Shih JW (1990) Clinical correlation and genetic polymorphism of the human immunodeficiency virus proviral DNA obtained after polymerase chain reaction amplification. Journal of Infectious Disease 162:1025-1030
13. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA & Chodakewitz JA (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine 337:734-739.
14. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ Jr, Feinberg JE, Balfour HH Jr, Deyton LR, Chodakewitz JA & Fischl MA (1997) A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. New England Journal of Medicine 337:725-733.
15. Hartman NR, Johns DG & Mitsuya H (1990) Pharmacokinetic analysis of dextran sulfate in rats as pertains to its clinical usefulness for therapy of HIV infection. AIDS Research and Human Retroviruses 6:805-811.
16. Ito M, Baba M, Sato A, Pauwels R, De Clercq E & Shigeta S (1987) Inhibitory effect of dextran sulfate and heparin on the replication of human immunodeficiency virus (HIV) in vitro. Antiviral Research 7:361-367.
17. Larder BA, Darby G & Richman DD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
18. Larder BA & Kemp SD (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246:1155-1158.
19. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN & Gregory TJ (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in chinese hamster ovary cells. Journal of Biological Chemistry 265:10373-10382
20. Lorentsen KJ, Hendrix CW, Collins JM, Kornhauser DM, Petty BG, Klecker RW, Flexner C, Eckel RH & Lietman PS (1989) Dextran sulfate is poorly absorbed after oral administration. Annals of Internal Medicine 111:561-566.
21. McClure MO, Whitby D, Patience C, Cheinsong-Popov R, Weber JN, Davies DS, Cook GMW, Keynes RJ & Weiss RA (1991) Dextrin sulfate and fucoidan are potent inhibitors of HIV infection in vitro. Antiviral Chemistry & Chemotherapy 2:149-156
22. McClure MO, Moore JP, Blanc DF, Scotting P, Cook GMW, Keynes RJ, Webe JN, Davies D & Weiss R (1992) Investigations into the mechanism by which sulfated polysaccharides inhibit HIV infection in vitro. AIDS Research and Human Retroviruses 8:19-26.
23. Mitsuya H, Looney DJ, Kuno S, Ueno R, Wong-Staal F & Broder S (1988) Dextran sulfate suppression of viruses in the HIV family: inhibition of virion binding to CD4+ cells. Science 240:646-649.
24. Moriya T, Kurita H, Matsumoto K, Otake T, Mori H, Morimoto M, Ueba N & Kunita N (1991) Potent inhibitory effect of a series of modified cyclodextrin sulfates (mCDS) on the replication of HIV-1 in vitro. Journal of Medicinal Chemistry 34:2301-2304.
25. Moriya T, Saito K, Kurita H, Matsumoto K, Otake T, Mori H, Morimoto M, Ueba N & Kunita N (1993) A new candidate for an anti-HIV-1 agent: modified cyclodextrin sulfate (mCDS71). Journal of Medicinal Chemistry 36:1674-1677.
26. Notermans DW, Jurriaans S, Wolf FD, Foudraine NA, de Jong JJ, Cavert W, Schuwirth CM, Kauffmann RH, Meenhorst PL, McDade H, Goodwin C, Leonard JM, Goudsmit J & Danner SA for the Ritonavir/3TC/ZDV Study Group (1998) Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. AIDS 12:167-173.
27. Otake T, Schols D, Witvrouw M, Naesens L, Nakashima H, Moriya T, Kurita H, Matsumoto K, Ueba N & De Clercq E (1994) Modified cyclodextrin sulfates (mCDS11) have potent inhibitory activity against HIV and high oral bioavailability. Antiviral Chemistry & Chemotherapy 5:155-161.
28. Ou CY, Kwok S, Mitchell SW, Mack DH, Sninsky JJ, Krebs JW, Feorino P, Warfield D & Schochetman G (1988) DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 239:295-297.
29. Paladin FJE, Monzon OT, Tsuchie H, Aplasca MRA, Learn Jr GH & Kurimura T (1998) Genetic subtypes of HIV-1 in the Philipines. AIDS 12:291-300.
30. Roberts NA (1995) Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 9 Suppl 2:S27-S32.
31. Schmit JC, Ruiz L, Clotet B, Raventos A, Tor J, Leonard J, Desmyter J, De Clercq E & Vandamme A-M (1996) Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 10:995-999.
32. Schols D, Struyf S, Van Damme J, Esté JA, Henson G & De Clercq E (1997) Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. Journal of Experimental Medicine 186:1383-1388
33. Stafford MK, Cain D, Rosenstein I, Fontaine EA, McClure M, Flanagan AM, Smith JR, Taylor-Robinson D, Weber J & Kitchen VS (1997) A placebo-controlled, double-blind prospective study in healthy female volunteers of dextrin sulphate gel. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 14:213-218.
34. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM & Blair ED (1995) Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrobial Agents and Chemotherapy 39:1704-1710.
35. Witvrouw M, Desmyter J & De Clercq E (1994) Antiviral portrait series: 4. Polysulfates as inhibitors of HIV and other enveloped viruses. Antiviral Chemistry & Chemotherapy 5:345-359.
36. Wong JK, Güthard HF, Havlir DV, Zhang Z-Q, Haase AT, Ignacio CC, Kwok S, Emini E & Richman DD (1997) Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proceedings of the National Academy of Sciences, USA 94:12574-12579.